Premium
The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL)
Author(s) -
Dare Julianne M,
Moppett John P,
Shield Julian PH,
Hunt Linda P,
Stevens Michael CG
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24689
Subject(s) - medicine , lymphoblastic leukemia , induction therapy , oncology , intensive care medicine , leukemia , immunology , chemotherapy
Abstract Hyperglycemia during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) has been inconsistently associated with risk of infection. We investigated the incidence of hyperglycemia during induction for childhood ALL in a retrospective cohort study of 144 patients treated on a single national protocol (UKALL2003) and explored its association with infection. All patients received dexamethasone. Overt hyperglycemia was seen in 36% and proven bacterial or fungal infection was most common in this group (OR 4.1 (1.1–15.6), P = 0.039). Both hyperglycaemia and infection were particularly common in patients with Down Syndrome. Pediatr Blood Cancer 2013;60:E157–E159. © 2013 Wiley Periodicals, Inc.